Earth Conservancy secures $6.7M grant for land reclamation and park development
Ostrowski said Earth Conservancy will use the grant to reclaim its 30-acre Hanover 7A site and transform it into a new community park serving the Lower South Valley.
Funded through DEP's highly-competitive Abandoned Mine Land Economic Revitalization (AMLER) Program, Ostrowski said the project highlights the power of partnerships in returning long-abandoned mine lands into valuable community assets — promoting both economic growth and environmental renewal.
Located in Hanover Township directly off State Route 29, Ostrowski said the site's accessibility makes it especially well-positioned to serve as a regional hub for outdoor recreation and community engagement.
"Earth Conservancy is incredibly grateful for the continued support from the Pennsylvania Department of Environmental Protection, as well as from our local representatives," Ostrowski said. "The site's accessibility and size make it ideal for a variety of outdoor activities. We genuinely believe it will not only provide a wonderful resource for residents, but also attract regional athletic tournaments, boosting our economy and fostering community engagement."
Project overview
Ostrowski said the history of Hanover 7A (H7A) is like many mine-scarred properties in EC's portfolio. Once owned by the Glen Alden Coal Company, the land was heavily strip-mined and left unrestored, with large open pits dominating the landscape. Its condition worsened after the Agnes Flood in 1972, when Pennsylvania designated non-operating strip mine sites — including 38 acres of H7A — for disposal of storm debris.
Following Glen Alden bankruptcy in the mid-1970s, Ostrowski said the land remained neglected until EC acquired it in 1994. At that time, he said no formal closure had occurred. EC worked with a range of agencies and community partners, including DEP, to evaluate and reclaim the 48-acre parcel.
Basic reclamation, including capping and grading, was completed in 2006. The site sat idle until 2019, when 18 acres were sold to a local developer, which became the new home of the Pennsylvania State Police Troop P barracks and training facility.
In January 2020, Ostrowski said EC convened a group of local stakeholders — including municipal leaders, elected officials, and representatives from area schools, colleges, and businesses — to discuss the site's potential.
"The response was overwhelmingly positive, with attendees envisioning the land becoming a focal point for community recreation and engagement," Ostrowski said.
In response, EC applied for and received a Community Conservation Partnership Program (C2P2) grant from the PA Department of Conservation and Natural Resources (DCNR) in 2021. Ostrowski said the funding supported site assessments, community outreach, and planning. Importantly, Ostrowski said the study confirmed that any reuse of the site — even for passive recreation — would require further reclamation.
To continue progress, Ostrowski said EC applied to DEP for funding through the AMLER Program in 2023.
In May 2025, Ostrowski said EC was awarded a $6.7 million AMLER grant to complete the next phase of the project. He said work will include bulk earthwork, grading, and subsurface stabilization; installation of basic utilities and parking areas; site revegetation; and construction of initial park amenities, including grass fields, a walking trail, and an inclusive playground.
"Once complete, the H7A project will mark a significant milestone in EC's mission to foster environmental restoration, economic development, and improved quality of life in the region," Ostrowski said. "The transformation of this long-neglected site into a vibrant community space will expand green infrastructure, enhance outdoor recreational opportunities, and serve as a valuable resource for local schools and residents. Additionally, the project lays the groundwork for future phases of development, supporting a healthier, safer, and more connected Lower South Valley."
Legislators offer comment
Sen. Lisa Baker, R-Lehman Township, said the project represents a terrific combination of conservation and recreation.
"We are fortunate to have a local group like the Earth Conservancy with the vision and energy to assemble and carry out a plan that contributes to the physical and mental health of area residents," Sen. Baker said. "This opens opportunities for those of all ages to enjoy the outdoors."
Rep. Alec Ryncavage, R-Hanover Township, said the project marks a transformative investment for Hanover Township and the entire region.
"Reclaiming abandoned mine land and turning it into a vibrant public space will not only improve our environment, but also create new recreational opportunities for families and support ongoing economic development," Rep. Ryncavage said. "I was proud to support this project and look forward to seeing it come to life."
Hanover Township Manager Sam Guesto said the township is grateful to the Earth Conservancy for securing these funds for a large recreation park.
"This park will benefit the community and region — fostering health, unity, and vibrant connections that enrich lives," Guesto said. "The township looks forward to supporting this very important project."
To learn more, visit www.earthconservancy.org.
Reach Bill O'Boyle at 570-991-6118 or on Twitter @TLBillOBoyle.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Zai Lab Establishes Oncology Scientific Advisory Board
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the creation of its Oncology Scientific Advisory Board (SAB). The newly formed Oncology SAB is comprised of distinguished oncology leaders and will support the advancement of the Company's robust oncology products and pipeline, including multiple internally developed investigational therapies. 'We are honored to bring together this esteemed group of oncology leaders who will support our continued development and advancement of innovative treatment options for patients globally,' said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. 'The formation of this Board is an important step for Zai; we know our clinical programs will benefit tremendously from the guidance and perspective of this highly regarded and experienced group of individuals.' Zai Lab's Oncology SAB comprises the following: Lieping Chen, M.D., Ph.D., is a United Technologies Corporation chair in cancer research, professor of immunobiology, dermatology and medicine at the Yale University School of Medicine. Richard S. Finn, M.D., is director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at University of California, Los Angeles (UCLA). Thomas F. Gajewski, M.D., Ph.D., directs the Melanoma Oncology Clinic and leads the Immunology and Cancer Program at the University of Chicago Comprehensive Cancer Center. Melissa L. Johnson, M.D., directs lung cancer research at the Sarah Cannon Research Institute. Matthew Krebs, M.D., Ph.D., is a clinical senior lecturer in experimental cancer medicine at the University of Manchester and leads early phase clinical trials at The Christie NHS Foundation Trust, Manchester, U.K. Patricia LoRusso, M.D., D.O., is director of the Early Phase Clinical Trials Program and Associate Center Director of Experimental Therapeutics at Yale Cancer Center. Michael T. Lotze, M.D., FACS, is professor of surgery, immunology and bioengineering, and director of the DAMP Laboratories at the University of Pittsburgh Medical Center Hillman Cancer Center. Timothy Yap, M.B.B.S., Ph.D., FRCP, is a medical oncologist, physician-scientist and professor at the University of Texas MD Anderson Cancer Center. About Zai Lab Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at Zai Lab Forward-Looking Statements This press release contains forward-looking statements relating to our future expectations, plans, and prospects for Zai Lab, including, without limitation, statements relating to our prospects and plans for developing and commercializing our oncology products and pipeline. These forward-looking statements may contain words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would,' and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and on the SEC's website at
Medscape
08-08-2025
- Medscape
Letter of Interest Tips for Residency Applicants
This transcript has been edited for clarity. What is a letter of interest? This is arguably the most important letter you are going to send when you are a medical student applying for a residency program in The Match. The letter of interest is one letter that you are going to be sending out to your top program. After you've interviewed at all of your different programs, you are going to rank onenumber one, and you are going to send a letter of interest. Mine was about five paragraphs, where I talked about all of the reasons why I thought I was a good fit at their program and why their program was a good fit for my life. Then, you send the letter of interest to that one program. It is crucial that you are only sending a letter of interest to one place because you are telling them that you're ranking them number one, and that you promise to do looks very bad if you end up sending a letter of interest to more than one program or if you send a letter of interest and end up not ranking them number one. It is a really important decision that you should think long and hard about, but it can really be a great strategy to let them know that you are really serious about going to that program.
Yahoo
02-08-2025
- Yahoo
TransMedics Group, Inc. (TMDX): A Bull Case Theory
We came across a bullish thesis on TransMedics Group, Inc. on Global Equity Briefing's Substack by Ray Myers. In this article, we will summarize the bulls' thesis on TMDX. TransMedics Group, Inc.'s share was trading at $118.97 as of July 31st. TMDX's trailing and forward P/E were 59.75 and 62.11 respectively according to Yahoo Finance. A surgeon in a modern operating theatre performing a transplant surgery with medical technology. TransMedics is revolutionizing the organ transplant ecosystem through its Organ Care System, a technology designed to keep organs warm, oxygenated, and viable far longer than traditional cold storage. By tackling key bottlenecks—organ degradation, low utilization rates, and logistical constraints—Organ Care System significantly extends transplant windows and boosts usage rates. Clinical trial data highlights its transformative potential: expanded criteria lungs and hearts saw utilization jump to 87% and 81%, respectively, while DCD heart use rose from 0% to 89%. TMDX monetizes this impact through a razor-and-blade model—selling Organ Care System consoles and high-margin, single-use consumables—while providing end-to-end services through its National Organ Care System Program, a SaaS-like Organs as a Service platform. With 21 private jets, 17 procurement hubs, and trained staff, TMDX handles organ retrieval, transport, and maintenance, positioning itself as a logistics powerhouse in the transplant chain. The opportunity is vast: U.S. underutilization alone represents a $400M+ annual consumables revenue potential, and TMDX currently serves just 3% of the $39B global market expected by 2034. Future growth catalysts include a kidney Organ Care System by 2029, entry into international markets via a $200M facility in Italy, and scaling the National Organ Care System Program globally. Financially, the company achieved profitability in 2024, posting $441M in revenue and positive operating cash flow, though free cash flow remains negative due to capex-heavy expansion. Trading at a P/E of 91, investor returns hinge on continued execution, EU rollout, and successful kidney platform launch. If goals are met, the stock could double by 2030, but slower expansion or margin compression may limit upside. Previously, we covered a on TransMedics Group, Inc. by Oliver | MMMT Wealth in May 2025, which highlighted warm perfusion technology, strong execution, and real-time flight data as revenue indicators. The company's stock appreciated ~24% since Q1 outperformance played out. Ray Myers shares a similar view but emphasizes the SaaS-like NOP model and global expansion potential. TransMedics Group, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held TMDX at the end of the first quarter which was 29 in the previous quarter. While we acknowledge the potential of TMDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.
